NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
MWN-AI** Summary
NexGelRx, the recent spin-off of NEXGEL, Inc., has received a strategic investment from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. Gruntfest will also take on the roles of board observer and strategic advisor for NexGelRx, leveraging his extensive expertise in reimbursement strategy and patient access to enhance the company's growth. With over 20 years in the healthcare sector, Gruntfest's background includes senior positions at major organizations such as Medtronic and Celgene, where he was pivotal in implementing patient support programs and reimbursement management strategies.
Richard Myers, CEO of NexGelRx, expressed enthusiasm for Gruntfest's involvement, highlighting the potential for their ultra-gentle hydrogel products to serve as innovative transdermal delivery mechanisms for pharmaceuticals. This investment aligns with NexGelRx's strategy of pursuing high-value opportunities in drug delivery while enabling NEXGEL to maintain its focus on contract manufacturing and consumer healthcare products.
NEXGEL is known for its high-water-content hydrogel products, applied across healthcare and consumer markets, with established brands like SilverSeal® and Turfguard®. The company’s capabilities in developing electron-beam cross-linked hydrogels have spanned over two decades, supported by strategic relationships with major consumer healthcare companies.
NexGelRx’s future prospects appear bright, drawing potential from the vast applications of their hydrogel technology in drug delivery systems. However, as with any forward-looking statements, there are inherent risks and uncertainties, and actual outcomes may differ significantly. Investors are cautioned to review the company's filings for a comprehensive understanding of the associated risks.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) recently made headlines with the announcement of strategic investments by Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC in their spin-off company NexGelRx. Gruntfest's appointment as a board observer and strategic advisor marks a significant strengthening of NexGelRx’s leadership, particularly with his extensive experience in reimbursement strategy and healthcare commercialization.
Given Gruntfest's expertise, investors should view this development as a bullish signal. His background in enhancing patient access and spearheading reimbursement management at prestigious firms, including Medtronic and Celgene, suggests he could play a vital role in navigating NexGelRx’s complex market landscape. As NexGelRx aims to leverage its ultra-gentle hydrogel technology for innovative transdermal drug delivery, the infusion of this strategic knowledge could accelerate its development timeline and increase its market viability.
Investors should also consider the broader context of NEXGEL’s offerings in the healthcare and consumer product industries. With a portfolio that includes distinctive high-water-content hydrogel products, the company's strategic focus appears well-timed, considering the growing demand in the healthcare sector for advanced drug delivery systems. The investment may also spark partnership opportunities and enhance NEXGEL’s position within consumer healthcare manufacturing, further driving revenue growth.
However, caution is warranted. Despite promising developments, NEXGEL's forward-looking statements emphasize inherent risks and uncertainties associated with their operational strategy and financial performance. Investors should closely monitor the company's progress on identified goals and their ability to execute on Gruntfest’s strategic insights.
Overall, this investment could position NEXGEL favorably, but as always in biotech, due diligence is essential in assessing potential risks and rewards.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthcare-commercialization leadership.
Mr. Gruntfest is a seasoned healthcare executive with over 20 years of experience spanning reimbursement management, payer solutions, and patient support programs. He currently serves as Managing Partner for Diesis Holdings, LLC, and as Chief Executive Officer of RMBB Health, where he has strengthened market positioning and advanced patient access initiatives. His background includes senior leadership roles at Medtronic, MiMedx, Shire, and Celgene, with a strong record of building and leading high-performing teams across the healthcare ecosystem.
“We welcome Eric as both an investor and strategic advisor to NexGelRx,” said Richard Myers, CEO of NexGelRx. “His insight will bring an important new perspective to our company and add to the depth of our stakeholder base. We have a unique, ultra-gentle hydrogel product, and we look forward to demonstrating its potential as an ideal, innovative transdermal delivery mechanism for a wide array of pharmaceuticals.”
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal ® , Hexagels ® , Turfguard ® , Kenkoderm ® and Silly George ® . Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, the potential return on investment for our shareholders through a dedicated team and platform to pursue high-value Rx opportunities while NEXGEL remains focused on contract manufacturing and consumer branded products in the health and beauty space, the potential to unlock what we believe to be a potentially large opportunity without NEXGEL itself having to fund its development, that electron beam generated hydrogel lends itself to creating new topical and systemic therapies that can supplement existing therapies or create new ways to treat patients in a variety of clinical areas and the focus of using the hydrogel for drug delivery platform could lead to it becoming a platform for a family of useful and transformative therapies . These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/ .
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ**
How does the strategic investment from Diesis Holdings, LLC impact the future development and commercialization of NexGelRx, particularly in relation to the NexGel Inc Warrant NXGLW?
What specific applications and pharmaceutical therapies does NexGelRx plan to pursue with its hydrogel drug delivery platform, potentially affecting shareholder value associated with the NexGel Inc Warrant NXGLW?
How does Eric Gruntfest's experience in reimbursement strategy and patient access influence NexGelRx’s approach to market entry and expansion, especially in the context of the NexGel Inc Warrant NXGLW?
Given the unique properties of the ultra-gentle hydrogel products, how does NexGelRx plan to differentiate its offerings in the competitive landscape, and how could this relate to the potential success of the NexGel Inc Warrant NXGLW?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
2.64% G/L:
$1.1701 Last:
19,819 Volume:
$1.15 Open:
